Evidence map›Paper›PMID 38527450›Full record

ArticleNeuro-degenerative diseases2023

Cerebral Tau Deposition in Comorbid Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis: An [18F]-Flortaucipir and 7T MRI Study.

Ian Cheong, Yong Du, Gwenn Smith, Jun Hua, Xu Li, Alexander Pantelyat

Open access · greenAbstract readCase Reports
In one paragraph

Article in Neuro-degenerative diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Comorbid pathologies and their impact on progressive supranuclear palsy: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Prevalence and impact of comorbidities in amyotrophic lateral sclerosis.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ian CheongDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yong DuDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gwenn SmithDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jun HuaDivision of MR Research, Johns Hopkins University School of Medicine, Department of Radiology and Radiological Science, Baltimore, Maryland, USA.
Xu LiDivision of MR Research, Johns Hopkins University School of Medicine, Department of Radiology and Radiological Science, Baltimore, Maryland, USA.
Alexander PantelyatDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USKennedy Krieger Institute · USJohns Hopkins University · US

Funding

Longitudinal Molecular Imaging of Neuropathology and Serotonin in Mild Cognitive ImpairmentR01AG059390 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2018 to 2022
$4.8M
Multi-modal magnetic resonance imaging in progressive supranuclear palsy (PSP)K23AG059891 · NIA · JOHNS HOPKINS UNIVERSITY · PI PANTELYAT, ALEXANDER Y. · 2018 to 2022
$968k
NIA NIH HHS K23 AG059891NIA NIH HHS R01 AG059390
6 · The paper itself

Abstract

introductionProgressive supranuclear palsy (PSP) is a four-repeat tauopathy characterized by multiple clinicopathologic subtypes. Advanced neuroimaging techniques have shown an early ability to distinguish PSP subtypes noninvasively for improved diagnosis. This study utilized tau PET imaging and MRI techniques at 7T to determine the neuroimaging profile of a participant with comorbid PSP and amyotrophic lateral sclerosis (ALS).

method[18F]-flortaucipir PET imaging was performed on one participant with PSP-ALS, one participant with typical PSP (Richardson's syndrome; PSP-RS), and 15 healthy control volunteers. Standardized uptake value ratio (SUVR) in each brain region was compared between PSP participants and controls. Quantitative susceptibility mapping (QSM) and inflow-based vascular-space occupancy MRI at 7T were performed on the two PSP participants and on two age-matched healthy controls to evaluate for differences in regional brain iron content and arteriolar cerebral blood volume (CBVa), respectively.

resultsIn the participant with PSP-ALS, the precentral gyrus demonstrated the highest [18F]-flortaucipir uptake of all brain regions relative to controls (z-score 1.94). In the participant with PSP-RS, [18F]-flortaucipir uptake relative to controls was highest in subcortical regions, including the pallidum, thalamus, hippocampus, and brainstem (z-scores 1.08, 1.41, 1.49, 1.32, respectively). Susceptibility values as a measure of brain iron content were higher in the globus pallidus and substantia nigra than in the midbrain and pons in each participant, regardless of group. CBVa values tended to be higher in the subcortical gray matter in PSP participants than in controls, although large measurement variability was noted in controls across multiple regions.

conclusionIn vivo tau PET imaging of an individual with PSP-ALS overlap demonstrated increased tau burden in the motor cortex that was not observed in PSP-RS or control participants. Consistent with prior PET studies, tau burden in PSP-RS was mainly observed in subcortical regions, including the brainstem and basal ganglia. QSM data suggest that off-target binding to iron may account for some but not all of the increased [18F]-flortaucipir uptake in the basal ganglia in PSP-RS. These findings support existing evidence that tau PET imaging can distinguish among PSP subtypes by detecting distinct regional patterns of tau deposition in the brain. Larger studies are needed to determine whether CBVa is sensitive to changes in brain microvasculature in PSP.

Indexed as

Amyotrophic Lateral SclerosisCarbolinesMagnetic Resonance ImagingPositron-Emission TomographySupranuclear Palsy, Progressivetau ProteinsBrainHumans7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinestau Proteins7TCBVFlortaucipirPETProgressive supranuclear palsyQuantative susceptibility mapping

Identifiers

PMID38527450
PMCPMC11132917
OpenAlexW4393162260

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.